Published in J Lipid Res on October 16, 2004
Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol (2007) 2.01
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
Nutritional systems biology modeling: from molecular mechanisms to physiology. PLoS Comput Biol (2009) 1.18
Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag (2007) 1.15
An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway. PLoS Comput Biol (2014) 1.03
Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments. J Lipid Res (2006) 0.92
Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. J Lipid Res (2009) 0.92
Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes (2013) 0.92
Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab (2013) 0.89
Stable isotope-labeled tracers for the investigation of fatty acid and triglyceride metabolism in humans in vivo. Clin Lipidol (2009) 0.89
A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans. J Lipid Res (2012) 0.85
Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing. J Lipid Res (2012) 0.81
A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. BMC Syst Biol (2012) 0.80
Using mass measurements in tracer studies--a systematic approach to efficient modeling. Metabolism (2008) 0.80
Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation. PLoS One (2014) 0.79
Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. J Am Heart Assoc (2015) 0.78
Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD. Mol Syst Biol (2017) 0.78
Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans. Front Physiol (2015) 0.76
Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models. PLoS One (2015) 0.75
A mathematical model of the sterol regulatory element binding protein 2 cholesterol biosynthesis pathway. J Theor Biol (2014) 0.75
A computational model for the analysis of lipoprotein distributions in the mouse: translating FPLC profiles to lipoprotein metabolism. PLoS Comput Biol (2014) 0.75
A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model. BMC Syst Biol (2013) 0.75
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab (2002) 6.79
Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet (2012) 5.16
Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation (2007) 4.62
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature (2002) 3.80
SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nat Cell Biol (2007) 3.69
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes (2005) 2.99
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 2.96
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet (2004) 2.86
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology (2015) 2.81
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care (2008) 2.73
The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res (2009) 2.59
Borrelia burgdorferi OspC protein required exclusively in a crucial early stage of mammalian infection. Infect Immun (2006) 2.54
Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science (2004) 2.38
Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol (2008) 2.33
Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26
[ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol (2011) 2.21
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart (2011) 2.17
Liver fat in the metabolic syndrome. J Clin Endocrinol Metab (2007) 2.17
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation (2005) 2.13
Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes (2007) 2.08
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet (2012) 1.97
Three novel mutations in the apolipoprotein E gene in a sample of individuals with type 2 diabetes mellitus. Clin Chem (2004) 1.83
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol (2011) 1.78
An immune response network associated with blood lipid levels. PLoS Genet (2010) 1.74
PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis (2012) 1.70
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. Eur Heart J (2010) 1.69
PLD1 and ERK2 regulate cytosolic lipid droplet formation. J Cell Sci (2006) 1.67
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol (2003) 1.65
Effects of a Mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects. Clin Sci (Lond) (2004) 1.63
Cytosolic lipid droplets increase in size by microtubule-dependent complex formation. Arterioscler Thromb Vasc Biol (2005) 1.62
Lipid droplets as dynamic organelles connecting storage and efflux of lipids. Biochim Biophys Acta (2008) 1.60
N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J (2012) 1.55
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care (2011) 1.53
Retracted The SNARE protein SNAP23 and the SNARE-interacting protein Munc18c in human skeletal muscle are implicated in insulin resistance/type 2 diabetes. Diabetes (2010) 1.51
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 1.51
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2005) 1.50
Postnatal constriction, ATP depletion, and cell death in the mature and immature ductus arteriosus. Am J Physiol Regul Integr Comp Physiol (2005) 1.49
Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families. Am J Hum Genet (2002) 1.45
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis (2005) 1.44
Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy. Atherosclerosis (2011) 1.42
Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc Natl Acad Sci U S A (2007) 1.41
Hypoxia converts human macrophages into triglyceride-loaded foam cells. Arterioscler Thromb Vasc Biol (2006) 1.40
SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J (2010) 1.40
Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring) (2009) 1.39
Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis (2003) 1.39
Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins. Arterioscler Thromb Vasc Biol (2006) 1.38
High-throughput shotgun lipidomics by quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.37
The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest (2011) 1.36
Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS (2002) 1.34
PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol (2010) 1.34
Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol (2002) 1.33
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes (2005) 1.32
Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) (2007) 1.31
Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem (2011) 1.31
Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc (2007) 1.29
Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet (2013) 1.26
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation (2003) 1.26
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol (2008) 1.26
Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis (2007) 1.26
Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. Hum Mol Genet (2005) 1.25
Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes (2008) 1.24
Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res (2007) 1.24